- About us
- Our people
- Cell therapy
- Gene therapy
- Small molecule
- Previous investments
- Message from Chief Executive, SIML
- Our social impact
- Responsible investor and partner
- Inspiring and empowering our people
- Responsible and ethical business
- Aligning with UN SDGs
- Syncona’s approach to charity
- Sustainability policies
- News and Insights
Building the next generation of global leaders in life science
We found, build and fund companies to translate exceptional science into transformational treatments for patients in areas of high unmet need.
Making a positive contribution
We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.
Annual Report and Accounts 2021
Our 2021 Annual Report and Accounts provides an overview of our most recent financial year, as we look to deliver on behalf of our stakeholders.
An expert multi-disciplinary team, attracting world-class talent
We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.
Leadership key facts*
members of the investment team
years of life science and investment expertise
investment team with PhDs
*All as of 31 March 2021